WO2004024145A1 - Action anticancereuse du carvedilol et de ses isomeres - Google Patents

Action anticancereuse du carvedilol et de ses isomeres Download PDF

Info

Publication number
WO2004024145A1
WO2004024145A1 PCT/US2002/028794 US0228794W WO2004024145A1 WO 2004024145 A1 WO2004024145 A1 WO 2004024145A1 US 0228794 W US0228794 W US 0228794W WO 2004024145 A1 WO2004024145 A1 WO 2004024145A1
Authority
WO
WIPO (PCT)
Prior art keywords
carvedilol
isomer
mixture
administered
cancer
Prior art date
Application number
PCT/US2002/028794
Other languages
English (en)
Inventor
Anand C. Burman
Rama Mukherjee
Manu Jaggi
Anu T. Singh
Original Assignee
Dabur Research Foundation
Cord, Janet, I.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dabur Research Foundation, Cord, Janet, I. filed Critical Dabur Research Foundation
Priority to AU2002336473A priority Critical patent/AU2002336473A1/en
Priority to PCT/US2002/028794 priority patent/WO2004024145A1/fr
Publication of WO2004024145A1 publication Critical patent/WO2004024145A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention provides for pharmaceutical compositions comprising carvedilol for treatment of cancer. More particularly the invention relates to the use of carvedilol for treatment of cancers of the colon, ovary, breast, prostate, pancreas, lung, melanoma, glioblastoma, oral cancer and leukemias.
  • the anticancer activity of carvedilol appears to be attributed to the inhibition of Epidermal Growth Factor and Platelet derived growth factor dependent proliferation of cancer cells.
  • carvedilol exerts anticancer effect by inhibition of the Protein kinase C (PKC) activity and that of the cyclooxygenase 2 enzyme.
  • PLC Protein kinase C
  • the invention also relates to the anticancer activity of the optically pure isomers S(-) and R(+) of carvedilol and the use of carvedilol and its isomers in pharmaceutical compositions for the treatment of cancer.
  • Carvedilol is a nonselective ⁇ -adrenergic blocking agent with ⁇ - adrenoreceptor blocking activity.
  • ( ⁇ )-l -(carbazol-4-yloxy)-3-[(2-(o- methoxyphenoxy) ethyl] amino]-2-propanol, better known as 'carvedilol' has the structural formula shown in figure 1. It is a racemic mixture.
  • Carvedilol is a white to off-white powder with a molecular weight of 406.5, represented by the molecular formula C 24 H 26 N 2 O 4 .
  • Carvedilol is a racemic mixture in which the S(-) enantiomer exhibits nonselective ⁇ -adrenoreceptor blocking activity and both R(+) and S (-) enantiomers at equal potency exhibit ⁇ -adrenergic blocking activity. Carvedilol has no intrinsic sympathomimetic activity.
  • Carvedilol is rapidly and extensively absorbed following oral administration due to a significant degree of first-pass metabolism. Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours. Carvedilol is extensively metabolized. Carvedilol is metabolized primarily by aromatic ring oxidation and glucuronidation. The oxidative metabolites are further metabolized by conjugation via glucuronidation and sulfation. The metabolites of carvedilol are excreted primarily via the bile into the faeces. Demethylation and hydroxylation at the phenol ring produce three active metabolites with ⁇ -receptor blocking activity. Based on preclinical studies, the 4'-hydroxyphenyl metabolite is approximately 13 times more potent than carvedilol for ⁇ -blockade.
  • Carvedilol is indicated for the treatment of mild or moderate heart failure of ischemic or cardiomyopathic origin, in conjunction with digitalis, diuretics, and ACE inhibitor, to reduce the progression of disease as evidenced by cardiovascular death, cardiovascular hospitalization, or the need to adjust other heart failure medications.
  • Carvedilol may be used in patients unable to tolerate an ACE inhibitor.
  • Carvedilol may be used in patients who are or are not receiving digitalis, hydralazine or nitrate therapy.
  • Carvedilol is also indicated for the management of essential hypertension. It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics.
  • Carvedilol is an antihypertensive drug with activity on ⁇ -adrenoceptors as well as calcium channel activity.
  • Use of carvedilol in compositions for treatment of congestive heart failure is disclosed in U.S. Patents 4,503,067 and 5,902,82.
  • U.S. Patent 4,369,326 discloses carbazolylmethane compounds useful as pressure sensitive or heat recording material. Also carvedilol has been explored for treatment of sexual impotence (U.S. Patent 5,399,581).
  • Patent 6,096,777 provides a new method for inhibiting the expression of Fas-mediated apoptosis using compounds which are dual non-selective ⁇ - adrenoceptor and ⁇ i-adrenoceptor antagonists such as carvedilol.
  • Carvedilol is reported to be a neurohumoral antagonist with multiple actions. Essentially a nonselective adrenergic receptor blocking agent, it has diverse reported properties viz. antioxidant and radical scavenging properties. It inhibits Mitogen activated protein kinase, a key serine / threonine kinase and cell cycle progression in vascular smooth muscle cells. (Sung etal, Pharmacology and Experimental therapeutics, Vol 283, Issue 2, 910-917, 1997)
  • the cellular signaling routes connecting the GPCRs to the Ras / MAPK pathway have known to involve Tyrosine kinases, PI3 kinases and/or PKC (Gutkind et al., J. Biol Chem, 273,1839-1842, 1998).
  • the ligand independent activation (transactivation) of receptor Tyrosine kinases viz. EGFR as a key cellular event in the activation of MAPK by specific G protein coupled receptors is also reported (Daub etal, EMBO J, 16, 7032-7044, 1997, Daub etal , Nature,379, 557-560,1996).
  • GPCR activation of Protein kinase C leading to EGFR transactivation and downstream MAPK activation maybe PKC mediated (Tsai etal, EMBO J, 16: 4597-4605, 1997), PKC prevented (Li X etal EMBO J, 17: 2574- 2583, 1998 ), or PKC independent (Daub et al., EMBO J, 16, 7032-7044, 1997, Daub etal , Nature,379, 557-560,1996
  • Tumor cells are well documented to produce autocrine and/or paracrine growth factors which can include platelet derived growth factor (PDGF), epidermal growth factor (EGF), transforming growth factor oc (TGFoc), colony stimulating growth factor l(CSF-l), and fibroblast growth factor (FGF).
  • PDGF platelet derived growth factor
  • EGF epidermal growth factor
  • TGFoc transforming growth factor oc
  • CSF-l colony stimulating growth factor l
  • FGF fibroblast growth factor
  • Growth factors regulate cell growth by activating multiple intracellular signal transduction pathways after binding to high affinity Tyrosine kinase receptors to the cell surface.
  • Protein kinase C is a family of closely related lipid dependent and diacylglycerol activated isoenzymes, with an important role in mitogenesis and tumor promotion.
  • PKC activity in vivo plays a critical role in regulation of proliferation and tumorigenesis (Blobe et al., Regulation of Protein kinase C and role in Cancer Biology, Cancer Metastasis Rev. 13 (3-4): 411-431, Dec. 13, 1994).
  • Acquired resistance to chemotherapy is a major problem during cancer treatment.
  • One mechanism for drug resistance is overexpression of the MDR1 (multidrug resistance) gene encoding for the transrnembrane efflux pump, P-glycoprotein (P-gp).
  • P-gp P-glycoprotein
  • Carvedilol influences doxorubicin (Dox) cytotoxicity and P-gp activity in a P-gp- expressing cell line compared to a non-expressing subline.
  • Carvedilol reduced P-gp activity approximately twice as effectively as verapamil at an equimolar concentration. This suggests that carvedilol has the clinical potential to reverse tumour MDR involving the efflux protein P-gp.
  • the invention involves methods for treating various types of cancer in patients using carvedilol or its optically pure isomers.
  • the present invention provides pharmaceutical compositions containing carvedilol or its optically pure isomers useful in the treatment of cancer.
  • the invention provides novel method for treating, inhibiting and/or preventing tumor growth or cancer growth.
  • Carvedilol Based on the multiple actions of Carvedilol, a study was undertaken to investigate the use of carvedilol for treatment of cancer. It was found by the inventors that carvedilol caused cytotoxicity on different human tumor cell lines depending on the dosage and cell-line used. Carvedilol was separated into its optically pure isomers S(-) and R(+) to determine their use as anticancer agents. The underlying cellular mechanism(s) that may be determining of the observed anticancer effects were investigated.
  • FIG. 1 shows the percent cytotoxicity of carvedilol at 20 mcg/ml.
  • Fig. 2 shows effect of carvedilol on EGF dependent proliferation in pancreactic cancer cells (MiaPaCa2) in vitro.
  • Fig. 3 shows effect of carvedilol on PDGF dependent proliferation in pancreatic cancer cells (MiaPaCa2) in vitro.
  • Fig. 4 shows effect of carvedilol on protein kinase C (PKC) activity in pancreatic cancer cells (MiaPaCa2) in vitro.
  • PDC protein kinase C
  • Fig. 5 shows effect of carvedilol on COX2 enzyme activity in pancreatic cancer cells (MiaPaCa2) in vitro.
  • Fig. 6 shows in vivo antirumor activity of carvedilol on B16F10 xenografts.
  • Carvedilol and its optically pure isomers were tested in various cell lines for their cytotoxic activity and it was found that these compounds can effectively be used for inhibition of tumors and cancer and for treatment of cancer or tumor. Such indications exhibited by these compounds are surprising as carvedilol is generally known to act as an anti-hypertensive drug and cytotoxic activity is not expected.
  • the modulation of Growth factor dependent proliferation as well as Protein kinase C, a key signaling intermediate involved in cross talk of G protein coupled signaling and receptor tyrosine kinases explained the observed anticancer effects of the molecule.
  • Pharmaceutical compositions containing an effective amount of the compounds of the invention as described herein above may be prepared according to methods known in the art.
  • the pharmaceutical compositions may provide from about 10 mg to 1000 mg of carvedilol or its isomers, per unit dose.
  • the actual dosage for humans and animals will vary depending upon the body weight of the subject, stage of affliction etc.
  • the composition may be administered either alone or as a mixture with other therapeutic agents.
  • compositions may be formulated in various physical forms suitable for administration such as tablets, capsules, solutions, injectables, lozenges, powders, aqueous or oily suspensions, syrups, elixirs, implants or aqueous solutions etc.
  • compositions containing carvedilol or an optically pure isomer thereof as active ingredients may be formulated as tablets, if intended for oral use, or lyophilized powders for parenteral administration.
  • the powders may be reconstituted by adding suitable diluents or pharmaceutically acceptable carriers prior to use.
  • Tablets containing carvedilol or an optically pure isomer thereof as active ingredient may include, along with non-toxic pharmaceutically acceptable excipients.
  • excepients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc.
  • the tablets may be uncoated or they may be coated by known techniques.
  • compositions for oral use may also be presented as hard gelatin capsules wherein the active ingredient comprises carvedilol or an isomer thereof mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.
  • an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
  • an oil medium for example peanut oil, liquid paraffin or olive oil.
  • compositions may also be formulated as solutions, when intended for systemic or parenteral administration.
  • Systemic administration refers to oral, rectal, nasal, transdermal and parentral (i.e., intramuscular, intraperitoneal, subcutaneous or intravenous).
  • the liquid formulation is generally buffered, isotonic or aqueous solution.
  • suitable diluents are normal isotonic saline solution, standard 5% dextrose in water or buffered sodium or ammonium acetate solution.
  • Formulations suitable for parenteral administration may also be used for oral administration or contained in a metered dose inhaler or nebulizer. It may be desirable to add excipients such as ethanol, polyvinylpyrrolidone, gelatin, hydroxy cellulose, acacia, polyethylene glycol, mannitol, sodium chloride or sodium citrate.
  • the compounds of the invention may be prepared in a emulsion or syrup for oral administration.
  • Pharmaceutically acceptable solid or liquid carriers may be added to enhance or stabilize the composition, or to facilitate preparation of the composition.
  • Liquid carriers include syrup, peanut oil, olive oil, glycerin, saline, ethanol, and water.
  • Solid carriers include starch, lactose, calcium sulfate dihydrate, terra alba, magnesium stearate or stearic acid, talc, pectin, acacia, agar or gelatin.
  • the carrier may also include a sustained release material such as glyceryl monostearate or glyceryl distearate, alone or with a wax.
  • the amount of solid carrier varies but, preferably, will be between about 20 mg to about 1 g per dosage unit.
  • the pharmaceutical preparations are made following the conventional techniques of pharmacy involving milling, mixing, granulating, and compressing, when necessary, for tablet forms; or milling, mixing and filling for hard gelatin capsule forms.
  • a liquid carrier When a liquid carrier is used, the preparation will be in the form of a syrup, elixir, emulsion or an aqueous or non-aqueous suspension. Such a liquid formulation may be administered directly or filled into a soft gelatin capsule.
  • compositions may contain additives selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents.
  • additives selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents.
  • the nature of pharmaceutical composition employed will, of course, depend on the desired route of administration.
  • the present invention provides for method(s) for the treatment of cancer or tumors, said method comprising the steps of administering to the subject an effective amount of carvedilol or an isomer thereof to a patient in need thereof.
  • the present invention provides for method(s) for the inhibition of cancer or tumors, said method comprising the steps of administering to the subject an effective amount of carvedilol or an isomer thereof to a patient in need thereof.
  • An effective amount of carvedilol or an isomer thereof is an amount sufficient to treat the cancer or tumor or inhibit the growth and or replication of the cancer or tumor.
  • the patient can be human, mammal or other animal.
  • the dosage in human beings for treatment of cancer or a tumor or inhibition of tumor or cancer includes the active ingredient (carvedilol or an isomer thereof) in combination with conventional pharmaceutical agents.
  • the usual dosage is about 3 to 30 g of active ingredient as a single dose or divided doses.
  • the preferred and actual dosage will be determined according to the specific compositions formulated, mode of administration, the site of administration and the patient being treated.
  • EXAMPLE 1 In vitro cytotoxicity and anti-cancer spectrum of carvedilol In vitro cytotoxic activity of carvedilol and its isomers was determined by performing the MTT cytotoxicity assay (Mosmann T., J Immunological Methods, 65:55; 1983). Briefly, the cultured tumor cells were separately seeded in a 96-well culture plate and co-incubated with carvedilol or its isomers dissolved in methanol, dimethyl formamide, dimethyl sulfoxide or isopropyl alcohol with relevant controls at 37°C in a CO 2 incubator. After 72 hours, the assay was terminated and percent cyotoxicities calculated.
  • Carvedilol shows good in vitro cytotoxicity in Human Colon, Ovary, melanoma, Leukemia, Glioblastoma, Prostate, oral and Lung tumor cell lines with ED 50 values less than 20 ⁇ g/ml. These results demonstrate that Carvedilol is a potential anti-cancer agent with broad-spectrum anticancer activity. Further, Figure 1 shows the high cytotoxicity effect of carvedilol on all of the above-mentioned tumor cell lines, except oral, at a fixed concentration of 20 ⁇ g/ml.
  • the anti-tumor activity of the optically pure isomers of Carvedilol S(-) and R(+) were evaluated in a 72-hour MTT cytotoxicity assay (Mosmaim T., J Immunological Methods, 65:55; 1983) as explained above.
  • Carvedilol and its isomers were evaluated in human tumor cell lines MOLT-4 (leukemia), PTC (colon), KB (oral), LI 32 (lung) U87MG (glioblastoma), HBL100 (breast), B16F10 (Melanoma), MiaPaCa.2 (Pancreas) and PA-1 (ovary) in a range of concentrations.
  • the ED 50 value (the test concentration which causes 50% cytotoxicity) as calculated graphically was used to compare the relative cytotoxic potential of Carvedilol and its isomers. As shown in Table 2, the active isomers have retained the cytotoxic potential of the parent compound Carvedilol. This shows that the optically pure isomers of Carvedilol are potential anti-cancer agents with the advantage of reduced compounded toxicities associated with the parent compound.
  • EXAMPLE 3 Effect of Carvedilol on Epidermal growth factor (EGF) dependent proliferation in vitro
  • the effect of Carvedilol on Epidermal growth factor (EGF) dependent proliferation was determined by the quantitation of percent viable cells in sera free conditions in vitro. Briefly, 10000 human pancreatic cancer cells (MiaPaCa2) were seeded per well in a 96-well culture plate in DMEM containing 5% FCS. All experiments were carried out in triplicates at 37°C in a CO 2 incubator. The cells were incubated for a period of 12 hours, washed once with PBS and the medium was changed to DMEM without Fetal calf serum (FCS). Carvedilol was dissolved in 1% DMSO in DMEM.
  • FCS Fetal calf serum
  • the cells were incubated with Carvedilol at a concentration of 20ug/ml for a period of 16 hours.
  • the untreated control cells were treated with 1% DMSO in DMEM.
  • the cells were washed with PBS and incubated with varying concentrations of EGF in DMEM without FCS for a period of 48 hours.
  • the percent viable cells in absence and presence of Carvedilol was determined in an MTT assay in vitro.
  • Carvedilol inhibits the EGF dependent proliferation in pancreatic cancer cells in a dose dependent manner in vitro.
  • PDGF Platelet derived growth factor
  • Carvedilol was dissolved in 1% DMSO in DMEM The cells were incubated with Carvedilol at a concentration of 20ug/ml for a period of 16 hours. The untreated control cells were treated with 1% DMSO in DMEM. The cells were washed with PBS, to remove Carvedilol and incubated with varying concentrations of PDGF in DMEM without FCS for a period of 48 hours. The percent viable cells in absence and presence of Carvedilol was determined in an MTT assay in vitro.
  • Figure 3 shows that Carvedilol inhibits the PDGF dependent proliferation in human pancreatic cancer cells in a dose dependent manner in vitro.
  • EXAMPLE 5 Effect of intracellular blocking of Protein Kinase C (PKC) on the cytotoxicity of Carvedilol in vitro
  • PKC Protein Kinase C
  • Carvedilol was added to the cells preincubated with or without Bisindolylmaleimide for 48 hours. Carvedilol was added every 24 hours. The percent cytotoxicity of Carvedilol in cells preincubated with or without Bisindolylmaleimide at non toxic concentrations was calculated, and the percent abrogation in the cytotoxicity determined. Table 3 shows the data on modulation of cytotoxicity of Carvedilol in presence or absence of Bisindolylmaleimide. As seen in table 3, blocking of PKC by Bisindolylmaleimide, abrogates the cytotoxicity of Carvedilol to a significant extent, suggesting a role for it in the observed anticancer action of Carvedilol.
  • EXAMPLE 6 Effect of intracellular blocking of PI3 kinase on cytotoxicity of Carvedilol in vitro.
  • the effect of PI3 kinase activation, on the cytotoxicity of Carvedilol was studied by the intracellular blocking of PI3 kinase, in cytotoxicity abrogation assays.
  • Carvedilol was added to the cells preincubated with or without Wortamannin for 48 hours. Carvedilol was added every 24 hours. The percent cytotoxicity of Carvedilol in cells preincubated with or without Wortmannin at non toxic concentrations was calculated, and the percent abrogation in the cytotoxicity determined. Table 4 shows the data on modulation of cytotoxicity of Carvedilol in presence or absence of Wortamannin. As seen in Table 4, the blocking of the activity of PI3 kinase by Wortamannin abrogates the cytotoxicity of Carvedilol, suggesting the role of the kinase in its observed action. TABLE 4
  • EXAMPLE 7 Effect of Carvedilol on PKC activity in vitro
  • PKC Protein Kinase C
  • ELISA Enyme linked immunosorbent assay
  • the cells were incubated with Carvedilol at concentrations of 5 - lOOug/ml for a period of 15 minutes at 37°C in 5% CO 2 .
  • the control cells were treated with 1% DMSO in DMEM.
  • the medium containing the Carvedilol was aspirated, and the cells were washed with Phosphate buffered saline (PBS) (50mM, pH 7.2) twice.
  • PBS Phosphate buffered saline
  • the cell pellet was dissolved in 1ml of ice cold sample preparation buffer (50mM Tris-HCl, 50mM 2-mercaptoethanol, lOmM EGTA, 5mM EDTA, lmM PMSF, lOmM Benzamidine, pH 7.5).
  • the cell pellets were sonicated four to five times each with time intervals of 5-10 seconds.
  • the cells were centrifuged at 100,000 x g for a period of 60 minutes at 4°C. The supernatant was aspirated from each set of experiments.
  • the reaction mixture for quantitation of the PKC activity contained 25mM Tris-HCl (pH7.0), 3mM Mgcl2, O.lmM ATP, 2mM CaC12, 50ug/ml Phosphatidylserine, 0.5mM EDTA, lmM EGTA, and 5mM 2 mercaptoethanol.
  • the lysates from the cells not treated with Carvedilol were the control experiments.
  • the reaction mixture was preincubated for 5 minutes at 25°C. 50ug of the cell lysate from different experiments was added to the individual reaction mix and added to microtitre plates coated with substrate for PKC. The plates were incubated for 15 minutes at 25°C in a water bath.
  • the PKC mediated reaction was stopped by the addition of 1 OOul of stop solution.
  • the plates were washed 5 times with the wash solution, and lOOul of the biotinylated antibody to the phosphorylated substrate was added per well.
  • the plates were incubated at 25°C for 60 minutes.
  • the plates were washed 5 times and lOOul of peroxidase conjugated streptavidin was added to each well.
  • the plates were incubated at 25°C for 60 minutes.
  • the plates were washed five times and lOOul of substrate was added to each well.
  • the plates were incubated at 25°C for 3-4 minutes, and the reaction was stopped by the addition of stop solution.
  • the optical density was read at 492nM, and the PKC activity expressed as percent of that in control cells.
  • Figure 4 shows the data on modulation of PKC activity by Carvedilol in pancreatic cancer cells as seen below, Carvedilol inhibits the PKC activity in a dose dependent manner
  • Example 8 Effect of carvedilol on activity of cyclooxygenase 2
  • Enzyme lx 10 6 human pancreatic cancer cells (MiaPaCa2) were plated in 6 well plates in RPMI containing 10% FCS. The cells were incubated for a period of 24 hours at 37°C in 5% CO 2 . The medium was changed to DMEM without serum. Carvedilol was dissolved in 1% DMSO in DMEM. The cells were incubated with Carvedilol at concentrations of lOug/ml and 20ug/ml for a period of 4 hours. All experiments were carried out in duplicates. The cells not treated with Carvedilol were the control experiments.
  • Cells were preincubated with Bisindolemaleimide (luM) , a specific inhibitor of PKC for 4 hours.
  • the medium was aspirated to remove Bisindolemaleimide, and the cells were washed twice with PBS.
  • These cells were treated with Carvedilol at lOug/ml and 20ug/ml .
  • the medium was removed in all wells after Carvedilol treatment, and 1ml of fresh medium containing Arachidonic acid (20uM) was added to the wells.
  • the cells were incubated at 37°C for one hour. Indomethacin at a concentration of lOug/ml was added to the wells to block the COX enzyme.
  • the intracellular and secreted levels of PGE2 were quantitated in cells treated with Carvedilol.
  • the cells were lysed (2.5% dodecyltrimethylammonium) and incubated for 10 minutes at room temperature.
  • the cell lysates were transferred to microtitre plate coated with goat anti mouse Ig coated plate.
  • 50 microlitre of PGE2 standards ranging from 2.5 to 320pg/ ml were added to the microtitre plate in duplicates.
  • 50 microlitre of mouse anti PGE2 and 50 microlitre of PGE2 conjugated peroxidase was added to the wells.
  • the plate was covered and incubated at room temperature for one hour on a microtitre plate shaker.
  • the wells were aspirated and washed 4 times with suitable was buffer.
  • 150 microlire of enzyme substrate was added to all the wells.
  • the plate was incubated for a period of 30 minutes and the colour development was stopped by the addition of IN sulphuric acid.
  • the levels of secreted and intracellular PGE2 were quantitated in the cells treated with Carvedilol and compared with that in untreated cells.
  • the levels of secreted and intracellular PGE2 were quantitated in cells treated with or without bisindolemaleimide.
  • Carvedilol inhibits the COX2 activity in pancreatic cancer cells in vitro.
  • the blocking of PKC by its specific inhibitor bisindolemaleimide abrogates the effect of Carvedilol on COX 2 activity, suggesting that it may be PKC mediated.
  • EXAMPLE 9 The antitumor activity of Carvedilol on Melanoma Tumor Xenografts grown in nude mice
  • Carvedilol The in vivo antitumor activity of Carvedilol has been demonstrated using the B16F10 melanoma xenograft model.
  • Melanoma tumor xenografts were initiated in Balb/c athymic mice by subcutaneous inoculation of a single cell suspension of B16F10 cells (10 X 10 cells/100 ⁇ L). The tumor-bearing mice were divided into three groups of 4 animals each.
  • Carvedilol was prepared at a concentration of 1.2 mg/ml so as to deliver a dose of 300 ⁇ g per 250 ⁇ l and 600 ⁇ g per 500 ⁇ l by Oral gavage once a day. The third group served as control. Treatment with Carvedilol was initiated on day 8.
  • Acute toxicity of Carvedilol in mice Carvedilol is used clinically in doses ranging between 6.5 mg/day to 100 mg/day in humans. Since most anti-cancer drugs have very narrow therapeutic indices we determined the therapeutic index of carvedilol in mice. Acute toxicity studies were performed using two preferred routes of administration: intravenous and oral administration. A range of doses between 0.1 to 10 mg was administered in mice using either the intravenous or oral routes and the animals were observed for two weeks. In Swiss albino mice, weighing 25 grams, lethal dose (6 mg oral, 1.25 mg i.v.) and safe dose (3 mg oral, 0.15 mg i.v.) was observed.

Abstract

L'invention concerne des compositions pharmaceutiques renfermant du carvedilol pour le traitement du cancer, et plus précisément l'utilisation du carvedilol pour le traitement des cancers suivants: colon, ovaire, sein, prostate, pancréas, poumon, mélanome, glioblastome, bouche et leucémie. Malgré l'absence de lien théorique, l'action anticancéreuse du carvedilol semble être imputable à l'inhibition de la prolifération des cellules cancéreuses dépendant du facteur EGF et du facteur de croissance dérivé des plaquettes. En outre, cette action repose sur l'inhibition de l'activité de la protéine kinase et de l'enzyme cyclo-oxygénase 2. L'invention concerne également l'action anticancéreuse des isomères optiquement actifs S(-) et R(+) du carvedilol et l'utilisation du carvedilol et de ses isomères dans des compositions pharmaceutiques pour le traitement du cancer.
PCT/US2002/028794 2002-09-10 2002-09-10 Action anticancereuse du carvedilol et de ses isomeres WO2004024145A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002336473A AU2002336473A1 (en) 2002-09-10 2002-09-10 Anti-cancer activity of carvedilol and its isomers
PCT/US2002/028794 WO2004024145A1 (fr) 2002-09-10 2002-09-10 Action anticancereuse du carvedilol et de ses isomeres

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/028794 WO2004024145A1 (fr) 2002-09-10 2002-09-10 Action anticancereuse du carvedilol et de ses isomeres

Publications (1)

Publication Number Publication Date
WO2004024145A1 true WO2004024145A1 (fr) 2004-03-25

Family

ID=31989874

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/028794 WO2004024145A1 (fr) 2002-09-10 2002-09-10 Action anticancereuse du carvedilol et de ses isomeres

Country Status (2)

Country Link
AU (1) AU2002336473A1 (fr)
WO (1) WO2004024145A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037259A2 (fr) * 2003-08-29 2005-04-28 Pharmacia Corporation Procedes et compositions de prevention ou de traitement de neoplasie comprenant un inhibiteur de la cox-2 en combinaison avec un antagoniste recepteur du facteur de croissance epidermale
WO2007042912A2 (fr) * 2005-10-13 2007-04-19 Orchid Research Laboratories Limited Nouveaux composes heterocycliques en tant qu'inhibiteurs de pstat3/il6
CN111825599A (zh) * 2019-04-17 2020-10-27 上海中医药大学附属龙华医院 新型Neddylation抑制剂的医药用途
US10851075B2 (en) 2007-09-10 2020-12-01 Sumitomo Dainippon Pharma Oncology, Inc. Stat3 pathway inhibitors and cancer stem cell inhibitors
CN113069447A (zh) * 2021-04-20 2021-07-06 上海市肺科医院 卡维地洛在制备sting激动剂和化疗增敏药物中的应用
US11299469B2 (en) 2016-11-29 2022-04-12 Sumitomo Dainippon Pharma Oncology, Inc. Naphthofuran derivatives, preparation, and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998007321A1 (fr) * 1996-08-23 1998-02-26 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beckman Corporation Limited Partnership No. 1 METHODE POUR INHIBER L'EXPRESSION DE Fas

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998007321A1 (fr) * 1996-08-23 1998-02-26 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beckman Corporation Limited Partnership No. 1 METHODE POUR INHIBER L'EXPRESSION DE Fas

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JONSSON O E ET AL: "Perivascular cell protection in vivo and increased cell survival in vitro by the antihypertensive agent carvedilol following radiation.", EUROPEAN JOURNAL OF CANCER, vol. 35, no. 8, August 1999 (1999-08-01), pages 1268 - 1273, XP002238563, ISSN: 0959-8049 *
LOTZE ULRICH ET AL: "Carvedilol inhibits platelet-derived growth factor-induced signal transduction in human cardiac fibroblasts.", JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, vol. 39, no. 4, April 2002 (2002-04-01), April, 2002, pages 576 - 589, XP009009274, ISSN: 0160-2446 *
SUNG CHENG-PO ET AL: "Carvedilol inhibits vascular smooth muscle cell proliferation.", JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, vol. 21, no. 2, 1993, pages 221 - 227, XP009009284, ISSN: 0160-2446 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037259A2 (fr) * 2003-08-29 2005-04-28 Pharmacia Corporation Procedes et compositions de prevention ou de traitement de neoplasie comprenant un inhibiteur de la cox-2 en combinaison avec un antagoniste recepteur du facteur de croissance epidermale
WO2005037259A3 (fr) * 2003-08-29 2005-08-04 Pharmacia Corp Procedes et compositions de prevention ou de traitement de neoplasie comprenant un inhibiteur de la cox-2 en combinaison avec un antagoniste recepteur du facteur de croissance epidermale
WO2007042912A2 (fr) * 2005-10-13 2007-04-19 Orchid Research Laboratories Limited Nouveaux composes heterocycliques en tant qu'inhibiteurs de pstat3/il6
WO2007042912A3 (fr) * 2005-10-13 2007-08-30 Orchid Res Lab Ltd Nouveaux composes heterocycliques en tant qu'inhibiteurs de pstat3/il6
US7786142B2 (en) 2005-10-13 2010-08-31 Orchid Research Laboratories, Ltd. Heterocyclic compounds as pSTAT3/IL-6 inhibitors
US10851075B2 (en) 2007-09-10 2020-12-01 Sumitomo Dainippon Pharma Oncology, Inc. Stat3 pathway inhibitors and cancer stem cell inhibitors
US11299469B2 (en) 2016-11-29 2022-04-12 Sumitomo Dainippon Pharma Oncology, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
CN111825599A (zh) * 2019-04-17 2020-10-27 上海中医药大学附属龙华医院 新型Neddylation抑制剂的医药用途
CN113069447A (zh) * 2021-04-20 2021-07-06 上海市肺科医院 卡维地洛在制备sting激动剂和化疗增敏药物中的应用

Also Published As

Publication number Publication date
AU2002336473A1 (en) 2004-04-30

Similar Documents

Publication Publication Date Title
US6632832B1 (en) Anti-cancer activity of carvedilol and its isomers
AU2002210993B2 (en) Medicinal compositions for concominant use as anticancer agents
CA2395461C (fr) Procedes de modulation de la fonction kinase de proteine tyrosine de type c-kit avec des composes indolinone
KR100386229B1 (ko) 히드록시카르바졸화합물의평활근유주및증식의억제
EP1604665B1 (fr) Inhibiteur de kinase c-kit
JP2022084953A (ja) 表皮水疱症及び関連する結合組織疾患の治療におけるカンナビノイドの局所製剤の使用
CN113750091A (zh) 用于治疗癌症的方法
KR20030003708A (ko) 시클로옥시게나제-2 활성의 저해
JP2003503456A (ja) 神経傷害またはアポトーシスを軽減する方法
JPWO2003074045A1 (ja) スルホンアミド含有複素環化合物及び血管新生抑制剤とを組み合わせてなる抗腫瘍剤
EP1435959A2 (fr) Methode de traitement du cancer thyroidien
JP2023504046A (ja) ジアリール大環状化合物を含む併用療法
TWI324604B (en) New use of staurosporine derivatives
KR20220148847A (ko) 다브라페닙, erk 억제제, 및 shp2 억제제를 포함하는 삼중 약학적 조합물
US20030105140A1 (en) Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof
AU2017235346B2 (en) Combination therapy for proliferative diseases
CN113164779A (zh) 治疗cdk4/6抑制剂耐药性癌症的方法
WO2004024145A1 (fr) Action anticancereuse du carvedilol et de ses isomeres
US20160067248A1 (en) Combinations
CZ59199A3 (cs) Způsob pro inhibici exprese Fas
Pollack et al. The efficacy of tamoxifen as an antiproliferative agent in vitro for benign and malignant pediatric glial tumors
EP1881826B1 (fr) Utilisation d'un derive benzoyle du 3-aminocarbazole pour le traitement d'un trouble associe a la production de prostaglandine e2 (pge2)
KR102152091B1 (ko) 뇌종양 줄기세포의 세포사멸 유도 활성을 갖는 카바졸 유도체 화합물의 용도
JP2023501912A (ja) 急性骨髄性白血病の治療のためのｄｈｏｄｈ阻害剤を含む組成物
CN115190800A (zh) 一种brd4抑制剂的用途

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP